Literature DB >> 6511233

The pharmacokinetics of subcutaneous bolus cytosine arabinoside in an arachis oil plus aluminium distearate suspension.

M L Slevin, E M Piall, A Johnston, D A Levison, G W Aherne, S B Tree, T A Lister.   

Abstract

An attempt was made to create a delayed release preparation of cytosine arabinoside (araC) which could be administered subcutaneously, and would produce plasma levels similar to steady state infusion concentrations. A thixotropic suspension of araC in arachis oil and aluminium distearate was formulated. This preparation was similar to that previously used with bleomycin oil suspension and procaine penicillin. Two hundred mg/ml of araC in arachis oil containing varying amounts of aluminium distearate were administered firstly to New Zealand White rabbits and then to patients with acute myelogenous leukaemia. This preparation was well tolerated by both rabbits and patients but did not delay the release of araC from the subcutaneous tissues.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6511233     DOI: 10.1007/bf00175376

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  12 in total

1.  [Not Available].

Authors:  J BUCHI; F O GUNDERSEN
Journal:  Pharm Acta Helv       Date:  1948-09-30

2.  Experimental evaluation of potential anticancer agents. XXI. Scheduling of arabinosylcytosine to take advantage of its S-phase specificity against leukemia cells.

Authors:  H E Skipper; F M Schabel; W S Wilcox
Journal:  Cancer Chemother Rep       Date:  1967-06

3.  Pharmacology of 5'-esters of 1-beta-D-arabinofuranosylcytosine.

Authors:  D H Ho; G L Neil
Journal:  Cancer Res       Date:  1977-06       Impact factor: 12.701

4.  Cytarabine for acute leukemia in adults. Effect of schedule on therapeutic response.

Authors:  J N Bickers; E A Gehan; E J Freireich; C A Coltman; H E Wilson; J S Hewlett; W J Stuckey; E J Van Slyck
Journal:  Arch Intern Med       Date:  1974-02

5.  2,2'-O-cyclocytidine, an antitumor cytidine analog resistant to cytidine deaminase.

Authors:  A Hoshi; F Kanazawa; K Kuretani; M Saneyoshi; Y Arai
Journal:  Gan       Date:  1971-04

6.  Phase I. evaluation of cyclocytidine (NSC-145668).

Authors:  J J Lokich; P L Chawla; N Jaffe; E Frei
Journal:  Cancer Chemother Rep       Date:  1975 Mar-Apr

7.  Clincal pharmacology of O2,2'-cyclocytidine.

Authors:  D H Rodriguez; T L Loo; G P Bodey; E J Freireich
Journal:  Clin Pharmacol Ther       Date:  1975-01       Impact factor: 6.875

8.  Cytosine arabinoside (NSC-63878) therapy for acute leukemia in adults.

Authors:  G P Bodey; E J Freireich; R W Monto; J S Hewlett
Journal:  Cancer Chemother Rep       Date:  1969-02

9.  The pharmacokinetics of subcutaneous cytosine arabinoside in patients with acute myelogenous leukaemia.

Authors:  M L Slevin; E M Piall; G W Aherne; A Johnston; M C Sweatman; T A Lister
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

10.  A radioimmunoassay for cytosine arabinoside.

Authors:  E M Piall; G W Aherne; V M Marks
Journal:  Br J Cancer       Date:  1979-10       Impact factor: 7.640

View more
  1 in total

1.  Delayed-release bleomycin. Comparative pharmacology of bleomycin oil suspension and bleomycin in saline.

Authors:  M L Slevin; V J Harvey; G W Aherne; N K Burton; A Johnston; P F Wrigley
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.